Updated efficacy and safety of lenvatinib (LEN) plus pembrolizumab (pembro) vs treatment of physician's choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Study 309/KEYNOTE-775

Authors :: Makker, V.
Colombo, N.
Casado Herraez, A.
Monk, B. J.
Mackay, H.
Santin, A. D.
Miller, D. S.
Publication Year :: 2022
Publisher :: Elsevier, 2022.
Abstract: Annual Meeting of the European-Society-for-Medical-Oncology (ESMO) -- SEP 09-13, 2022 -- ELECTR NETWORK<br />[No Abstract Available]<br />European Soc Med Oncol<br />Eisai Inc., Nutley, NJ, USA; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<br />Eisai Inc., Nutley, NJ, USA, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Tools